BRIEF—NeuroVive partners with brain injury experts to advance candidate

Stockholm-based NeuroVive Pharmaceutical is to partner with TRACK-TBI, a network of US-based traumatic brain injury (TBI) clinicians and researchers, to “create synergies, share know-how and leverage resources,” to further clinical progress against the condition.

TRACK-TBI’s principal investigator Geoffrey Manley pointed to “promising results with NeuroVive's TBI candidate drug NeuroSTAT,” stating that such partnerships were “essential to our overall goal of accelerating the process of translating advances in TBI research.”

Mitochondrial medicine expert NeuroVive plans to initiate a Phase II efficacy study for NeuroSTAT this year, the design of which will draw from TRACK-TBI’s expertise.

CEO Erik Kinnman said the collaboration would grant NeuroVive “access to the world's top TBI clinicians and researchers,” and “facilitate our goal to deliver a medicine that protects the brain of TBI patients in the acute stage.”